Prestige Consumer Healthcare (PBH) Stock: Buy, Sell, or Hold?
PBH - Prestige Consumer Healthcare Inc.
$46.95
-0.39 (-0.82%)
▼
5d:
-10.67%
30d:
-10.18%
90d:
-1.3%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When PBH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PBH is down 10.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PBH is down 10.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$71.86
Based on 4.8% avg growth
INTRINSIC VALUE TODAY
$44.62
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBH is currently trading at $46.95, which is considered oversold relative to its 30-day fair value range of $49.79 to $53.36. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.8) compared to its historical average (11.9). Remarkably, the market is currently pricing in an annual earnings decline of 6.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PBH is showing support break momentum. The price is currently testing key support at $46.48. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PBH scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $67.80 (+44.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PBH is showing support break momentum. The price is currently testing key support at $46.48. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PBH scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $67.80 (+44.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$49.79 -
$53.36
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 44.4% below Wall St target ($67.80)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$49.79 -
$53.36
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$46.48
Resistance Level
$53.95
Current Trend
Support Break
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.80
Wall Street Target
$67.80
(+44.4%)
Revenue Growth (YoY)
6.5%
Earnings Growth (YoY)
-35.8%
Profit Margin
15.6%
Valuation Discount vs History
-6.1% cheaper
PE vs Historical
9.8 vs 11.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.1%
(market-implied from PE analysis)
1-Year Target
$44.09
(-6%)
2-Year Target
$41.40
(-12%)
3-Year Target
$38.87
(-17%)
3-Yr Target (if PE normalizes)
(PE: 10→12)
$47.18
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 5.5%)
$113.36
(+141%)
Base:
(SPY PE: 9.8, Growth: 5.5%)
$55.10
(+17%)
Bear:
(PE: 8.3, Growth: 5.5%)
$46.83
(0%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 13.56 | Current EPS (TTM): $3.49
Bull Case
$71.45
(+52%)
Analyst growth 37.2%, PE expands to 14.9
Base Case
$64.96
(+38%)
Market implied 37.2%, PE stable at 13.6
Bear Case
$32.19
(-31%)
Severe decline -20.0%, PE contracts to 11.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.8 to 11.9
Stabilization Target:
$56.99
(+21.4%)
PE Expansion Potential:
+21.4%
Share & Embed Analysis
Last updated: September 12, 2026 10:53 AM ET
Data refreshes hourly during market hours. Next update: 11:53 AM
Data refreshes hourly during market hours. Next update: 11:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
